Bacteriophage Therapy: An Alternative to Antibiotics—An Experimental Study in Mice

Gopal Nath^{1,2} Ram Janam¹ Rajesh Kumar² Mayank Gangwar²

¹Laboratory of Bacteriophage Therapy and Functional Genomics, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India

²Department of Microbiology, Viral Research and Diagnostic Laboratory, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India

Address for correspondence Gopal Nath, MD, PhD, FAMS, Department of Microbiology, Viral Research and Diagnostic Laboratory, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh 221005, India (e-mail: gopalnath@gmail.com).

Ann Natl Acad Med Sci (India) 2019;55:151–158

Abstract

Keywords

- *Pseudomonas aeruginosa*
- bacteriophage cocktail
- multidrug resistant
- mouse model

The present study was planned to evaluate the efficacy of *Pseudomonas aeruginosa* specific phages in immunocompromised septicemia animal model as an alternative to antibiotics. Five different sets of experiments were performed: prophylactic administration of phage cocktail (3 lytic and unique) before and simultaneous with bacterial challenge; and therapeutic, that is, administration of phage cocktail 6, 12, and 24 hours after the bacterial challenge. No mortality was observed when simultaneous and late administration of phages was done with respect to the bacterial challenge. Contrary to this, administration of phage cocktail 100 µL (10^{12} PFU/mL) of volume after 6 hours of the infection resulted in a mortality rate of 60%. However, no mortality could be observed with reduced dose of cocktail, that is, 10^8 , 10^9 , and 10^{10} PFU administered 6 hours after bacterial challenge. Phage therapy in acute infections initiated with very small dosage under strict supervision may give better results. However, further studies to determine the quantity and frequency of dosage of phage cocktail for septicemia of various durations is strongly indicated.

Introduction

Pseudomonas aeruginosa is a metabolically least demanding gram-negative bacterium that can cause a wide range of opportunistic infections. Individuals with open wounds (burn and trauma), cancer, immunocompromised cystic fibrosis, and septicemia are particularly susceptible to *P. aeruginosa* infections.^{1–3} Environmental signals during infection cause several genotypic and phenotypic changes enabling *P. aeruginosa* to survive in the form of planktonic cells, colonies, or biofilms.⁴ The increasing frequency of multidrug-resistant strains is particularly concerning as treatment options are severely limited in the absence of effective antibiotics.^{5,6} The problem has reached such a dimension that, at global level, United Nations General Assembly was called in New York in September 2016 to decide the plan for fighting antimicrobial resistance together. This was only the fourth time in the history of the UN that a health topic

was discussed at the General Assembly. Other three were HIV, noncommunicable diseases, and Ebola. The delegates and heads of the nations addressed the seriousness and scope of the situation and agreed on sustainable, multisector approaches to address the issue of antimicrobial resistance. The different alternatives suggested are; newer antibacterial molecules, antibacterial peptides, bacteriocins, probiotics, prebiotics, and bacteriophage therapy. Even if a given antibiotic molecule is effective in vitro against the infecting strain, it may fail in vivo because of biofilm formation leading to poor permeation of antibiotics at the infection site. In case of *P. aeruginosa*, it has been observed that in biofilm profile, it may resist biocides up to 100 times greater than the planktonic or free swimming cells.⁷ Rigorous research activities are going on to develop alternatives toward the treatment of infections caused by *P. aeruginosa*. Ironically, active immunization against *P. aeruginosa* in immunocompromised patients has got no relevance.⁸ Of these, the phage therapy

has emerged as one of most promising alternative to overcome the problem of bacterial resistance.⁹ The capacity of phages through production of highly specific enzymes like polysaccharide depolymerases or alginate lyases to eradicate bacterial biofilms is an important aspect toward their successful implementation in *in vivo* treatments. Phage cocktails have been applied as alternative or as supportive treatments simultaneously with antibiotics for *P. aeruginosa* eradication causing various infections, such as purulent wounds, septicemia, urinary tract, or lung infections. Many of the previous studies have given conflicting results due to several confounding factors.⁹⁻¹⁷ However, the commercialization of the phage therapy is still far away due to lack of convincing preclinical and clinical trials. Hence, prior to translation of phage therapy into clinical settings, vigorous experimental authentications with extensive *in vitro* and *in vivo* studies are needed. The present study, therefore, was planned to see the efficacy of *P. aeruginosa* specific bacteriophage cocktail in septicemia in burn induced immunocompromised mouse model in different experimental settings.

Materials and Methods

Bacterial Strains and Their Identification

P. aeruginosa isolates were isolated from clinical specimens (pus, blood, urine, cerebrospinal fluid [CSF], wound swabs, etc.) collected from the patients admitted to intensive care unit of a tertiary level university hospital of Banaras Hindu University on *Pseudomonas* selective media (cetrimide agar). The strains were identified by the methods already described in standard text. The study period extended from December 2012 to July 2014.

All the clinical isolates were identified as *P. aeruginosa* by using standard biochemical and molecular methods. Further study was conducted only on *P. aeruginosa* confirmed isolates. Antimicrobial susceptibility test of *P. aeruginosa* was done by the standard Bauer–Kirby disc diffusion method. The size of inhibition zones were recorded and interpreted according to the Clinical and Laboratory Standards Institute (CLSI) breakpoint guideline 2012. All the *P. aeruginosa* strains were tested for their susceptibility to gentamicin (GEN, 10 µg), amikacin (AK, 30 µg), netilmicin-sulfate (NET, 30 µg), carbenicillin (CB, 100 µg), piperacillin/tazabactam (PTZ, 100/10 µg), ceftriaxone (CTR, 30 µg), ceftazidime (CAZ, 30 µg), cefepime (CPM, 30 µg), imipenem (IPM, 10 µg), meropenem (MRP, 10 µg), ertapenem (ETP, 10 µg), ciprofloxacin (CIP, 5 µg), levofloxacin (LE, 5 µg), ofloxacin (OF, 5 µg), cotrimoxazole (COT, 25 µg), polymyxin-B (PB, 300 unit), chloramphenicol (C, 30 µg), colistin sodium methanesulfonate (CI, 25 µg), and azithromycin (AZM, 15 µg).

Phage Isolation and Purification

Isolation of bacteriophages was done from different water sources (river, ponds, and sewer) by using double agar overlay method with slight modification as described earlier.¹⁷ In brief, for isolation of bacteriophages, the *P. aeruginosa* was plated as lawn culture (10^8 CFU/mL) on Mueller–Hinton agar (MHA). Water specimens from different water bodies were

treated with 1% chloroform (v/v) for 20 minutes and centrifuged for 15 minutes at $10,778 \times g$. The supernatant in the volume of 1 mL was flooded on the 5-hour old lawn culture growth (log phase) of the *P. aeruginosa* (isolated strains from different hosts) on 90-mm nutrient agar plate and incubated overnight at 37°C. Next day the lawn was washed with 3 mL TMG (Tris-HCl, magnesium sulfate, and gelatin pH 7.4) buffer and centrifuged at $10,778 \times g$ for 15 minutes. The supernatant (1 mL) was transferred to a 1.5 mL microcentrifuge tube. One drop of chloroform was added and mixed well by vortexing or by inversion for 15 minutes. Centrifugation was done at $10,778 \times g$ for 10 minutes. The lawn culture in log phase of the host was again prepared and the supernatant collected as mentioned above was inoculated in the volume of 100 µL at 10 to 12 places to screen for lysis. The surface with clear plaque was cut and collected in 1 mL of the TMG buffer and propagated further and plaque counting was done by soft agar overlay method.¹⁸ The single isolated plaque was picked up for further processing. The number of phage particle was increased by soft agar overlay method. After bulk production, the bacteria were killed by 1% chloroform and centrifuged. The clear supernatant was preserved at 4°C for further use. For purification (toxin free) and concentration of phages the harvested fluid was subjected to membrane dialysis against polyethylene glycol (PEG 6,000; 20% in 2.5 M NaCl) for overnight and then washed with PBS (phosphate buffer saline) at 4°C. This process was repeated twice at 4°C.

Assessment of Anti-*P. aeruginosa* Activity of Bacteriophages

Bacteriophage Host Range Determination

All the 35 isolated phages were subjected to the assessment of their antibacterial activity on a total of 100 clinical isolates of *P. aeruginosa*. The lawn culture of *P. aeruginosa* (10^8 CFU/mL) was made on MHA. Each of the phages having concentration of 10^9 plaque forming unit (PFU)/mL was spotted on the plate in the volume of 10 µL. The plates were observed for the clear zone after overnight incubation at 37°C. Each phage was tested against all the bacterial strains in duplicate in independent experiments.

Isolation of Bacteriophage DNA

Isolation of phage DNA was performed with phenol/chloroform and ethanol precipitation method. Briefly, purified phage particles (10^{10} – 10^{12} PFU/mL) were treated with 1 µg of DNase I and RNase A (Bangalore Genei, Bangalore, India) at 37°C for 30 minutes. To the mixture, proteinase-K (Bangalore Genei, Bangalore, India), and SDS were added at a final concentration of 0.05 mg/mL and 0.5% respectively and incubated at 56°C. After 1 hour of incubation, an equal volume of phenol:chloroform was added to remove proteinaceous material. The extraction was repeated thrice with phenol–chloroform–isoamyl alcohol (25:24:1). The nucleic acid was precipitated with chilled ethanol and suspended in 20 µL of TE buffer (10 mM Tris-HCl, pH = 7.0; 1.0 mM EDTA, pH = 7.0) according to standard procedure.¹⁹

Genotyping of Bacteriophages by ERIC-PCR

All the bacteriophages were subjected to genotyping by ERIC-PCR (used on the principle of RAPD). This test was used to genotype the phages to see whether they were genotypically similar or different. This test enabled us to pick up the phages which were not only different in antibacterial activity wise but different genotypically also. The primer sequences used for ERIC and PCR conditions are given in ►Table 1. The ERIC primers were used like RAPD with 49°C as annealing temperature rather than 61°C.²⁰ PCR was performed in 25 µL volume using 10 ng of genomic DNA, 1 U of Taq polymerase (Bangalore Genie, India), and 15 pmol of each primer (Bangalore Genie), 200 mmol/L (each) deoxynucleotide triphosphate (Bangalore Genie, India), and 2 mmol/L MgCl₂ in standard PCR buffer. Amplification reactions were performed in a thermal cycler (Biometra, Goettingen, Germany).

Preparation of Dendrogram

The gel images were analyzed under ultraviolet light using a gel documentation system (BioRad, Universal Hood II, United States). The size of DNA bands were estimated according to molecular weight markers. Cluster analysis of all the 22 bacteriophages was done on the basis of the fingerprints generated. Based on the banding patterns obtained from ERIC-PCR, dendrogram was constructed. For each phage a haplotype matrix or a binary table was manufactured by linearly composing lysis (1) and no lysis (0), data derived from gel analysis of ERIC-PCR. The resulting similarity matrix was used as the input data for cluster analysis by NTSYS pc2.0 program of UPGMA.²¹

Phage Cocktail Preparation

The three most potent bacteriophages φpsbhu-1, φpsbhu-15, and φpsbhu-17 were purified and made toxin free with membrane dialysis (dialysis membrane-135, HiMedia Laboratories Pvt. Ltd. Mumbai, India). A phage cocktail containing equal concentration and volume of above three phages were titrated at 1×10^{12} PFU/mL. These phages were different from each other genotypically based on ERIC PCR and also activity wise on 100 indicator strains of *P. aeruginosa*.

Animal Model Studies

The study protocol was approved by Institute Animal Ethics Committee of Banaras Hindu University.

Safety of Bacteriophage Cocktail

A group of 10 adult Swiss albino mice approximately 6 to 8 weeks old were taken and 100 µL intraperitoneal (I/P) injection of phage cocktail consisting of φpsbhu-1, φpsbhu-15, and φpsbhu-17 at the concentration of approximately 2×10^{12} PFU/mL was given to them without anesthesia

and burn injury. These mice were observed for 1 month. None of the mice was found sick or dead.

Determination of LD100

A group of 10 adult Swiss albino mice approximately 6 to 8 weeks old on antibiotic free diet were taken and anaesthetized with help of optimum dose of ether. Care was taken to avoid deep anesthesia. Mice were placed into a template with an opening of 4.5 cm by 1.8 cm to expose their shaved backs. Third-degree thermal injury to the skin was induced by the exposed back area to the coin template dipped into 90°C water for 10 seconds. About 0.8 mL ofringer's lactate solution was administered immediately following the burn. The mice were challenged by intraperitoneal injection of 100 µL (inoculums containing 1×10^6 to 1×10^9 CFU/mL) the *P. aeruginosa* strain (PS BHU-17), was resistant to gentamicin, netilmicin, amikacin ceftazidime, meropenem, ciprofloxacin, and piperacillin/tazobactam but sensitive to tobramycin, was isolated from a burn wound of a patient. The mice were kept under observation in an ambient environment. It was observed that all the mice died between 36 and 72 hours of the infection. Liver, spleen, heart, and peritoneum fluids of dead mice were collected at postmortem examinations. Individual organs were weighted and suspended in 2 mL of PBS. They were then homogenized using Wheaton overhead stirrers. The homogenate was plated on MHA plate to see the bacterial growth.

Assessment of Clinical Efficacy of the Phage Cocktail

We used phage cocktail as prophylactic, as well as therapeutic purposes. The mice experiments were set up in following groups and each group contained five mice.

Group A

Bacteriophage cocktail was given at constant dose, that is, in the volume of 100 µL containing 10^{12} PFU/mL. Further, the bacterial challenge of 100 µL of *P. aeruginosa* in the concentration of 1×10^9 CFU/mL was given in all the settings of this section of the study.

A.1) Simultaneous administration of bacteriophage and *P. aeruginosa* challenge:

The above mentioned dosage of bacterial challenge and bacteriophage cocktail was given in the different flanks through intraperitoneal route.

A.2) Bacteriophage cocktail 6 hours later to bacterial challenge:

The bacterial challenge was given 6 hours later to the initial prophylactic protection by the dose mentioned above. The mice were observed for 96 hours.

A.3) Bacteriophage cocktail 6 hours before bacterial challenge:

Table 1 Primer set, annealing temperature, amplicon size, and references of the protocol used in the study

Gene targets	Oligos	Annealing Temperature	Amplicon size (bp)	Reference
ERIC-PCR	F-5'-ATGTAAGCTCCTGGGGATTAC-3' R-5'-AAGTAAGTGACTGGGGTGAGCG-3'	49°C	Multiple	²⁰

Initially the bacterial challenge was given and 6 hours later the bacteriophage cocktail was given in the different flank of abdomen.

A.4) Bacteriophage cocktail 12 hours after bacterial challenge:

Initially the bacterial challenge was given and 12 hours later the bacteriophage cocktail was given in the different flank of abdomen.

A.5) Bacteriophage cocktail 24 hours after bacterial challenge:

Initially the bacteria challenge was given and 24 hours later the bacteriophage cocktail was given in the different flank of abdomen.

Group B

Assessment of Phage Efficacy after Decreasing the Volume of Phage Cocktail

Bacteriophage cocktail 6 hours after bacterial challenge of 20, 40, and 60 μL of approximately 2×10^{12} PFU/mL of the three different dosages were given to three different groups (five mice in each group).

Grading of diseases: The grading of the disease was done as follows: grade-I, normal when there was no obvious change seen in the experimental animals; grade II was given to those mice who had slight illness, lethargy and ruffled fur; grade-III scoring was given to the mice having moderate illness, severe lethargy, ruffled fur, and hunched back; grade IV to those having severe illness with above sign, exudative accumulation around eyes; and grade V to those who died at the point of examination.

Statistical Analysis

Data were expressed as means $\pm$ standard deviation (SD) of mean and statistical analysis was performed with Wilcoxon's signed-ranked test using student's *t*-test for calculations of mean and SD. Difference with $p \leq 0.05$ was considered as statistically significant.

Results

Safety of Bacteriophage Cocktail

When the phage cocktail was given at the concentration of approximately 2×10^{12} PFU/mL, none of the mice was found sick or dead when observed for 1 month.

Determination of LD100

The challenge bacterial strain could give 100% mortality in 36 to 48 hours at the dose of 100 μL 1×10^9 CFU/mL.

Prophylactic Treatment

Simultaneous Administration of Bacteria and Phage Cocktail

No mortality occurred in any mice. The score of morbidity is given in ►Table 2.

Bacteriophage Cocktail 6 Hours before Bacterial Challenge

Result of prophylactic study states that only two (20%) out of 10 treated mice died after 12 hours. However, rest of eight

mice (80%) survived and recovered to normal healthy level after 72 hours of the infection.

Administration of *P. aeruginosa* 6 Hours before Bacteriophage Cocktail

In our result, death of six mice out of 10 mice was observed within 24 hours of infection and remaining four mice recovered to normal healthy after 72 hours of infection.

Administration of *P. aeruginosa* 12 Hours before Bacteriophage Cocktail

In our result, none of the mice died in this group. Only they remain sick up to 48 hours and after 72 hours they recovered to normal healthy.

Administration of *P. aeruginosa* 24 Hours before Bacteriophage Cocktail

In our result, none of the mice died in this group. Only they remain sick up to 48 hours and after 72 hours they recovered to normal healthy.

Concentration Dependent Phage Cocktail

We observed that none of the mice died in these three groups as described above. However, the mice of given 60 μL of phage cocktail was observed more sick at 24 hours than the rest of two groups. Further recovery was very slow in the group received 20 μL of phage cocktail (►Fig. 1).

Assessment of Phage Efficacy after Decreasing Volume of Phage Cocktail after 6 Hours of Bacterial Challenge

Bacteriophage cocktail 6 hour after bacterial challenge of 20, 40, and 60 μL of approximately 2×10^{12} PFU/mL of the three different dosage were given to three different groups (five in each group) of mice.

Bacteriophage Cocktail Dose having 60 μL of Approximately 2×10^{12} PFU/mL

A total of three out of five mice belonging to this group had increased severity and developed additional sign of exudative accumulation around the eyes. No death was noted. In the rest of the mice severe illness persisted at 72 hours but improved and became normal at 96 hours (►Fig. 1).

Bacteriophage Cocktail Dose having 40 μL of Approximately 2×10^{12} PFU/mL

This group receiving 40 μL of approximately 2×10^{12} had severe illness persisting up to 72 hours with the peak at 24 hours. In this group also severe illness continued up to 72 hours. However, all of them became healthy after 96 hours.

Bacteriophage Cocktail Dose having 20 μL of Approximately 2×10^{12} PFU/mL

This group receives 20 μL of approximately 2×10^{12} of the cocktail. All the five mice had all the signs of severe infection at 24 hours after the start of the therapy. The sickness persisted up to 72 hours with complete recovery at 96 hours (►Fig. 2).

Table 2 The effect of bacteriophage therapy in different experimental groups along with criterion for scoring

Observation made after intervention with bacteriophages at 12, 24, 48, 72, and 96 hours					
A. Bacteriophage cocktail given in the volume of 100µl containing 10 ¹¹ PFU (10 mice in each group)	12	24	48	72	96
I) Simultaneous administration of bacteriophage and <i>Pseudomonas aeruginosa</i> challenge	2 ^a +2+3+3+3+2+3+2+2+3 (2.5)	3+3+3+3+3+3+3+3+3+3 (3.0)	2+3+3+3+2+2+3+3+2+3 (2.6)	1+1+1+1+1+1+1+1+1+2 (1.1)	1+1+1+1+1+1+1+1+1+1 (1.0)
II) Bacteriophage cocktail 6 h before bacterial challenge	2+2+3+3+3+3+3+3+3+3 (2.8)	3+3+5+3+3+5+3+3+3+3 (3.4)	2+2+5+3+3+5+2+3+3+3 (3.2)	2+2+5+2+2+5+2+2+2+2 (2.6)	1+1+5+1+1+5+1+1+1+1 (1.8)
III) Bacteriophage cocktail 6 h after bacterial challenge	5+5+3+3+5+5+3+2+5+3 (3.9)	5+5+3+3+5+5+5+3+5+3 (4.2)	5+5+3+3+5+5+5+3+5+3 (4.2)	5+5+2+1+5+5+5+5+5+1 (3.5)	5+5+1+1+5+5+5+5+5+1 (3.4)
IV) Bacteriophage cocktail 12 h after bacterial challenge	2+3+3+3+3+3+3+2+3+3 (2.8)	3+3+3+3+3+3+3+3+3+3 (3.0)	2+3+3+3+3+3+3+3+3+3 (2.9)	1+2+1+1+1+2+1+2+1+1 (1.3)	1+1+1+1+1+1+1+1+1+1 (1.0)
V) Bacteriophage cocktail 24 h after bacterial challenge	2+2+3+3+3+3+3+2+3+3 (2.7)	3+3+3+3+3+3+3+3+3+3 (3.0)	2+2+3+3+3+3+2+3+2+2 (2.6)	1+2+1+1+1+1+1+1+1+3 (1.3)	1+1+1+1+1+1+1+1+1+1 (1.0)
B. Bacteriophage cocktail given in the volume of 100µl					
IIIA) Bacteriophage cocktail 6 h after bacterial challenge (dose 1.6x10 ¹⁰ PFU) ^b	2+3+2+3+3 (2.6)	3+3+3+3+3 (3.0)	1+1+1+1+1 (1.0)	1+1+1+1+1 (1.0)	1+1+1+1+1 (1.0)
IIIB) Bacteriophage cocktail 6 h after bacterial challenge (dose 2.5x10 ⁹ PFU) ^b	2+2+2+2+2 (2.0)	2+1+1+2+2 (1.6)	1+2+1+2+2 (1.6)	1+1+1+1+1 (1.0)	1+1+1+1+1 (1.0)
IIIC) Bacteriophage cocktail 24 h after bacterial challenge (dose 5x10 ⁸ PFU) ^b	2+2+2+3+3 (2.4)	2+2+3+3+3 (2.6)	2+2+3+3+3 (2.6)	1+1+2+2+1 (1.4)	1+1+1+1+1 (1.0)

Note: 1–Normal; 2–Slight illness, lethargy, ruffled fur; 3–Moderate illness, severe lethargy, ruffled fur and hunched back; 4–Severe illness with above sign, exudative accumulation around eyes; 5– Death; Figure in parenthesis shows the average of the signs of all the 5 mice in a particular study group.

^aGrading of diseases.

^bExperiment done on 5 mice only.

Discussion

This study was aimed to evaluate the efficacy of bacteriophage cocktail as an alternative antibacterial therapy to deal with the MDR/XDR/PDR strain of *P. aeruginosa* leading to severe morbidity and mortality in clinical settings, especially septicemia and pneumonia. The focus of the study was to evaluate the protective effect when phage therapy is started at different time intervals after setting up the infection and also to have clues regarding dosage of the cocktail.

For the purpose, *P. aeruginosa* isolate resistant to all the available antipseudomonal drugs was picked up. The dose of 100 µL (10⁹ CFU/mL) of the bacterium was found to result into 100% mortality between 24 and 48 hours when injected intraperitoneally. On postmortem examination pure *P. aeruginosa*

isolation from all the vital organs established the cause of death due to the bacterium. Further, we prepared the cocktail of the three different and the most virulent bacteriophages and tested them for safety in five healthy mice injecting through IP route. We observed no adverse effect. To assess the efficacy of cocktail at a random concentration (10¹² PFU/mL) administered at different time points as patient may report to intensive care units at different intervals after ensuing the *P. aeruginosa* septicemia. Five different sets of experiments having 10 mice in each group were performed. The first group received bacteriophage cocktail as prophylactic antibacterial administered simultaneously with the challenge dose of the bacterium considering that infection caused by *P. aeruginosa* may occur soon after inflicting the wound. We found that the severity of disease was minimal resulting into no mortality. This observation indicates that the

Fig. 1 Effect of pseudomonas aeruginosa and bacteriophage cocktail for clinical grading of diseases based of time of inoculation. Disease grading denoted by numbering 1: normal; 2: slight illness, lethargy, and ruffled fur; 3: moderate illness, severe lethargy, ruffled fur and hunched back; 4: severe illness with above sign, exudative accumulation around eyes; 5: death. Group I: bacteriophage (Ø) + bacteria simultaneously; group II: pretreatment of Ø 6 hours before bacterial challenge; group III: Ø 6 hours later bacterial challenge; group IV: Ø 12 hours later bacterial challenge; group V: Ø 24 hours later bacterial challenge.

Fig. 2 Effect of pseudomonas aeruginosa at reduced dosage when bacteriophage cocktail was given 6 hours later bacterial challenge for clinical grading of diseases based on the time of inoculation. Disease grading denoted by numbering 1: normal; 2: slight illness, lethargy, and ruffled fur; 3: moderate illness, severe lethargy, ruffled fur and hunched back; 4: severe illness with above sign, exudative accumulation around eyes; 5: death. Group III: bacteriophage (Ø) cocktail (100 µL) given 6 hours later to bacterial challenge; group IIIA: Ø cocktail (60 µL) given 6 hours later to bacterial challenge; group IIIB: Ø cocktail (40 µL) given 6 hours later to bacterial challenge; group IIIC: Ø cocktail (20 µL) given 6 hours later to bacterial challenge.

P. aeruginosa specific bacteriophage cocktail prevents the death if given in advance before the infection sets in. However, in the second group when the bacterial challenge was given 6 hours before the bacteriophage cocktail, the mortality in the mice was 60%. The third experimental group, the bacteriophage cocktail given 6 hours before the bacterial challenge, led to death of 20% of the mice. However, when same dose of cocktail was evaluated after 12 and 24 hours of the initiation of the infection process, there was no mortality in both the groups. This might have occurred because of the fact that around 6 hours of the bacterial and phage challenges, the dosage of cocktail and *in vivo* multiplied *P. aeruginosa* might have reached at the optimal concentration (zone phenomenon) leading to massive lysis causing severe endotoxic shock. While in groups 4 and 5, the bacteriophages might have been adsorbed on the host bacteria replicating gradually and causing gradual lysis of the bacteria. This assumption made us to reduce the doses

of cocktail in volume to in three different groups of mice to 60, 40, and 20 µL in place of 100 µL given 6 hours later to bacterial challenge. These decrease dosage delivered phages at the concentration of 1.6×10^{10} , 2.5×10^9 , and 5×10^8 PFU in place of 10^{11} PFU. This modification caused no death in the challenged mice 6 hours before the cocktail, although recovery was delayed with the lowest dosage. No death after decrease in dosage might have occurred on the hypothesis that the septicemia being an acute condition, even the small dose of phages replicating in the blood and other tissues where *P. aeruginosa* are actively multiplying and this will slow down the release of the endotoxins and also cure the infection without causing endotoxic shock as liver and kidney are able to tackle the situation. This suggested that the lower dosage of the bacteriophage cocktail may be better with less risk of mortality. It is preliminary study in the area of septicemia and phage therapy and therefore many more questions remain to be answered. Importantly, the question that

why there was mortality in particular group/s? Is it the sudden bacterial lysis leading massive release of endotoxins and other toxins which is stimulating release and exhaustion of cytokines (tumor necrosis factor [TNF]- α , INF- β INF- γ , interleukin [IL]-1, IL-6, etc.) and also causing multiorgan failure? This phenomenon has also been speculated in cases of clinical septicemia where antibiotics acting on cell wall (penicillin, cephalosporins, and carbapenems) are administered as a bolus.²² There is another study in healthy rats, where intravenous bolus of 30 mg of ceftazidime per kg caused to a substantial increase in IL-6 and TNF- α concentrations in serum.²³ This observation suggests that the increase in parameters of inflammation occurring after initiation of ceftazidime therapy may be a consequence not only of the release of proinflammatory bacterial compounds. Whereas cell wall-active antibacterials can temporarily enhance the liberation of toxic or proinflammatory bacterial compounds, bactericidal antibiotics acting by the inhibition of RNA, or protein synthesis or DNA replication (rifamycins, macrolides, clindamycin, ketolides, and quinolones) delay or even circumvent bacterial lysis.²⁴

However, this speculation needs to be confirmed by estimating the counting of bacteria and bacteriophages at different intervals, estimating the endotoxins levels, and proinflammatory cytokines at variable dosage of the bacteriophages. Here, it is pertinent to mention that similar observation has been made with phage therapy in *Acinetobacter baumannii* immunocompromised mouse septicemia model (unpublished data).

Therefore, it may be suggested to see the levels of bacteremia and monitoring of different cytokines and endotoxin in mouse septicemia model to translate the phage therapy in life threatening *P. aeruginosa* septicemia. The possibility of gradual increase in cocktail dosage or single small dose may be explored for its safety and efficacy also.

Conclusion

In conclusion, this study strongly supports the use of bacteriophages as therapeutic agents to combat MDR, XDR, and PDR *P. aeruginosa* infections in immunocompromised patients.

Note

The author was selected for Dr. Pran Nath Chhuttani Oration for the year 2018-2019.

Ethical Approval

The study protocol was approved by Institute Animal Ethics Committee.

Funding

We gratefully acknowledge that this research was supported by Department of Biotechnology, Govt. of India, New Delhi, India, in the form of Junior Research Fellowship to Ram Janam.

Conflict of Interest

None declared.

References

- 1 Trautmann M, Lepper PM, Haller M. Ecology of *Pseudomonas aeruginosa* in the intensive care unit and the evolving role of water outlets as a reservoir of the organism. *Am J Infect Control* 2005;33(5, Suppl 1):S41-S49
- 2 Lyczak JB, Cannon CL, Pier GB. Establishment of *Pseudomonas aeruginosa* infection: lessons from a versatile opportunist. *Microbes Infect* 2000;2(9):1051-1060
- 3 Schroeder TH, Reiniger N, Meluleni G, Grout M, Coleman FT, Pier GB. Transgenic cystic fibrosis mice exhibit reduced early clearance of *Pseudomonas aeruginosa* from the respiratory tract. *J Immunol* 2001;166(12):7410-7418
- 4 Bragonzi A, Paroni M, Nonis A, et al. *Pseudomonas aeruginosa* microevolution during cystic fibrosis lung infection establishes clones with adapted virulence. *Am J Respir Crit Care Med* 2009;180(2):138-145
- 5 Breidenstein EBM, de la Fuente-Núñez C, Hancock REW. *Pseudomonas aeruginosa*: all roads lead to resistance. *Trends Microbiol* 2011;19(8):419-426
- 6 Poole K. *Pseudomonas aeruginosa*: resistance to the max. *Front Microbiol* 2011;2:65
- 7 Brooun A, Liu S, Lewis K. A dose-response study of antibiotic resistance in *Pseudomonas aeruginosa* biofilms. *Antimicrob Agents Chemother* 2000;44(3):640-646
- 8 Priebe GP, Goldberg JB. Vaccines for *Pseudomonas aeruginosa*: a long and winding road. *Expert Rev Vaccines* 2014;13(4):507-519
- 9 Pires DP, Vilas Boas D, Sillankorva S, Azeredo J. Phage therapy: a step forward in the treatment of *Pseudomonas aeruginosa* infections. *J Virol* 2015;89(15):7449-7456
- 10 Debarbieux L, Leduc D, Maura D, et al. Bacteriophages can treat and prevent *Pseudomonas aeruginosa* lung infections. *J Infect Dis* 2010;201(7):1096-1104
- 11 Kumari S, Harjai K, Chhibber S. Bacteriophage versus antimicrobial agents for the treatment of murine burn wound infection caused by *Klebsiella pneumoniae* B5055. *J Med Microbiol* 2011;60(Pt 2):205-210
- 12 Khawaldeh A, Morales S, Dillon B, et al. Bacteriophage therapy for refractory *Pseudomonas aeruginosa* urinary tract infection. *J Med Microbiol* 2011;60(Pt 11):1697-1700
- 13 Watanabe R, Matsumoto T, Sano G, et al. Efficacy of bacteriophage therapy against gut-derived sepsis caused by *Pseudomonas aeruginosa* in mice. *Antimicrob Agents Chemother* 2007;51(2):446-452
- 14 Golkar Z, Bagasra O, Pace DG. Bacteriophage therapy: a potential solution for the antibiotic resistance crisis. *J Infect Dev Ctries* 2014;8(2):129-136
- 15 Rossitto M, Fiscarelli EV, Rosati P. Challenges and promises for planning future clinical research into bacteriophage therapy against *Pseudomonas aeruginosa* in cystic fibrosis. An argumentative review. *Front Microbiol* 2018;9:775
- 16 McVay CS, Velásquez M, Fralick JA. Phage therapy of *Pseudomonas aeruginosa* infection in a mouse burn wound model. *Antimicrob Agents Chemother* 2007;51(6):1934-1938
- 17 Chan BK, Turner PE, Kim S, Mojibian HR, Eleftheriades JA, Narayan D. Phage treatment of an aortic graft infected with *Pseudomonas aeruginosa*. *Evol Med Public Health* 2018;2018(1):60-66
- 18 Ellis EL, Delbrück M. The growth of bacteriophages. *J Gen Physiol* 1939;22(3):365-384
- 19 Sambrook J, Fritsch EF, Maniatis T. *Molecular Cloning: A Laboratory Manual*, 2nd ed. New York, NY: Cold Spring Harbor Laboratory Press, Cold Spring Harbor
- 20 Versalovic J, Koeuth T, Lupski JR. Distribution of repetitive DNA sequences in eubacteria and application to fingerprinting of bacterial genomes. *Nucleic Acids Res* 1991;19(24):6823-6831

- 21 Romesburg HC, Cluster Analysis for Researchers. Morrisville, NC: Lulu Press; 2004
- 22 Nau GJ, Richmond JF, Schlesinger A, Jennings EG, Lander ES, Young RA. Human macrophage activation programs induced by bacterial pathogens. Proc Natl Acad Sci U S A 2002;99(3):1503–1508
- 23 Horii T, Ichiyama S, Ohta M, Kobayashi M. Relationship between morphological changes and endotoxin release induced by carbapenems in *Pseudomonas aeruginosa*. J Med Microbiol 1999;48(3):309–315
- 24 Prins JM. Antibiotic induced release of endotoxin clinical data and human studies. J Endotoxin Res 1996;3(3):269–273